• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2012 Product Image

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2012

  • Published: December 2012
  • 82 pages
  • Global Markets Direct

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma). Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Basal Cell Carcinoma (Basal Cell Epithelioma) Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) 9
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics under Development by Companies 11
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Products under Development by Companies 17
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics Development 19
F. Hoffmann-La Roche Ltd. 19
Biofrontera AG 20
Millennium Pharmaceuticals, Inc. 21
Novartis AG 22
LEO Pharma A/S 23
4SC AG 24
Cannabis Science, Inc. 25
Moberg Derma AB 26
Basal Cell Carcinoma (Basal Cell Epithelioma) – Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
vismodegib - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
vismodegib - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Aminolevulinic acid hydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ingenol mebutate - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
HPPH - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
silicon phthalocyanine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
erismodegib - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
erismodegib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
tazarotene - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
LEQ-506 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Dz-13 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
TAK-441 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
imiquimod - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
vismodegib - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
CS-TATI-1 Research Program - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Hedgehog Inhibitor - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
WNT Inhibitor - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
interferon alfa-2b + interferon gamma-1b - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Interleukin-15 Recombinant - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Drug Profile Updates 60
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Discontinued Products 70
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics - Dormant Products 71
Basal Cell Carcinoma (Basal Cell Epithelioma) – Product Development Milestones 72
Featured News & Press Releases 72
Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma 72
Jun 07, 2012: Curis Announces Publication Of Erivedge Data In New England Journal Of Medicine 72
May 17, 2012: Curis Announces Presentation Of Erivedge Clinical Data At ASCO Annual Meeting 74
May 07, 2012: Curis Announces Collaborator Roche's Submission Of Erivedge For Registration With Australian Regulatory Authority 75
Mar 09, 2012: Moberg Derma Receives Approval To Initiate Clinical Trial For Limtop 76
Jan 30, 2012: Curis Announces FDA Approval Of Erivedge Capsule As First Treatment For Advanced Basal Cell Carcinoma 76
Dec 22, 2011: Curis Announces Roche's Submission Of Marketing Authorization Application For Vismodegib In Advanced Basal Cell Carcinoma 77
Nov 15, 2011: Moberg Derma Receives SEK4m From Vinnova For Development Of Limtop 78
Nov 09, 2011: Curis Announces FDA Acceptance And Priority Review Of NDA For Vismodegib As Treatment For Advanced Basal Cell Carcinoma 78
Sep 12, 2011: Genentech Submits New Drug Application To FDA For Vismodegib For Basal Cell Carcinoma 79
Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 82
Disclaimer 82

List of Tables
Number of Products Under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2012 9
Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma) – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
F. Hoffmann-La Roche Ltd., H2 2012 19
Biofrontera AG, H2 2012 20
Millennium Pharmaceuticals, Inc., H2 2012 21
Novartis AG, H2 2012 22
LEO Pharma A/S, H2 2012 23
4SC AG, H2 2012 24
Cannabis Science, Inc., H2 2012 25
Moberg Derma AB, H2 2012 26
Assessment by Monotherapy Products, H2 2012 27
Assessment by Combination Products, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 32
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Drug Profile Updates 60
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Discontinued Products 70
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics – Dormant Products 71

List of Figures
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2012 9
Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma) – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Discovery and Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 27
Assessment by Combination Products, H2 2012 28
Assessment by Route of Administration, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 30
Assessment by Molecule Type, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 32

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos